TPD & Induced Proximity Summit Leaderboard
  • Monday, June 22, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 72

Author

Pharma Journalist 8887 posts 0 comments

FDA Grants Priority Review for WINREVAIR Label Update Following ZENITH Trial Results

Jul 3, 2025
Merck, known as MSD outside the U.S. and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental Biologics License…
Read More...

FDA Grants Accelerated Approval to ZEGFROVY, First Oral EGFR‑Exon‑20 Insertion NSCLC Therapy

Jul 3, 2025
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to ZEGFROVY (sunvozertinib), a novel oral therapy developed by Dizal, for the treatment of adults with…
Read More...

Adagene Secures Up to $25M Strategic Investment from Sanofi

Jul 3, 2025
Adagene Inc., a biotechnology company developing innovative antibody-based cancer therapies, announced that Sanofi will invest up to $25 million in the company as part of an expanded…
Read More...

Lynozyfic (linvoseltamab-gcpt) Granted FDA Accelerated Approval for Relapsed/Refractory Multiple…

Jul 3, 2025
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic (linvoseltamab-gcpt) to treat adult patients…
Read More...

Riliprubart Earns Orphan Drug Designation in Japan for CIDP

Jul 2, 2025
The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to riliprubart, an investigational monoclonal antibody developed by Sanofi, for the…
Read More...

FDA Approves Gamifant as First Treatment for MAS in Still’s Disease

Jul 1, 2025
Sobi announced that the U.S. Food and Drug Administration (FDA) approved Gamifant (emapalumab-lzsg) for the treatment of adult and pediatric (newborn and older) patients with…
Read More...

FDA Eases Monitoring Rules, Removes REMS from BMS Cell Therapies

Jul 1, 2025
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi (lisocabtagene maraleucel;…
Read More...

Vetter Breaks Ground on New Clinical Site

Jul 1, 2025
Vetter, a leading, globally operating Contract Development and Manufacturing Organization (CDMO), celebrated the start of construction for its new clinical manufacturing site in Des…
Read More...

Piramal Pharma Solutions Breaks Ground on $90M Expansion

Jul 1, 2025
Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd., recently announced a $90M investment plan to…
Read More...

AbbVie to Acquire Capstan Therapeutics, Advancing Immunology Innovation

Jul 1, 2025
AbbVie and Capstan Therapeutics, Inc. announced a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class in vivo tLNP anti-CD19…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.